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Abstract
Background: Nidogens are highly conserved proteins of basement membranes. Two nidogen
proteins, nidogen 1 and nidogen 2, are known in mammals.
Results: We show that CpG islands of both NID1 and NID2 genes are aberrantly methylated in
human cancer samples and cancer cell lines. For both genes, methylation was correlated with loss
of gene transcription in human cell lines. Furthermore, demethylation of the NID1 and NID2
promoters restored gene transcription, demonstrating that methylation was responsible for
silencing nidogen genes. In primary tumors, we detected NID1 promoter methylation in 67% of
colon cancer samples and in 90% of gastric cancers. NID2 promoter was methylated in 29% of
colon and 95% of gastric cancers. Immuno-staining for nidogen-2 confirmed the correlation
between aberrant methylation and loss of nidogen expression also in primary tumors, implying that
aberrant methylation was a mechanism for inhibiting nidogens expression in human gastrointestinal
tumors.
Conclusion: These results suggest that loss of nidogens expression has a potential pathogenetic
role in colon and stomach tumorigenesis. Nidogens are believed to connect laminin and collagen
IV networks, hence stabilizing the basement membrane structure. Nidogens are also important for
cell adhesion, as they establish contacts with various cellular integrins. Loss of nidogen expression
may favor invasion and metastasis of cancer cells by loosening cell interaction with basal membrane
and by weakening the strength of the basement membrane itself, first barrier from the connective
vascularized matrix.
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Background
Basement membrane is a thin layer of specialized extracel-
lular matrix. Its main components include collagen IV,
laminins, heparan sulfate proteoglycan (perlecan) and
nidogens. It can be found under sheets of epithelial and
endothelial cells and surrounding muscle, fat and muscle
cells. It is essential for tissue compartmentalization and
maintenance of cell phenotypes; it also supplies stimuli
for tissue development and remodeling [1,2].
Among its components, nidogen binds and forms ternary
complex with collagen IV and laminin, connecting the
two networks and stabilizing the tri-dimensional structure
of the basement membrane [3]. Nidogen thus serves the
important role of establishing and maintaining basement
membrane and tissue architecture.
Nidogen also interacts with cell receptor molecules and
controls cell polarization, migration and invasion.
Nidogen-1, in particular, interacts with β1  family of
integrin receptors and with αvβ3 integrin [4-7]. Through
interactions with the leukocyte response integrin, nidogen
favors neutrophil chemotaxis during the inflammation
process. The interactions between cells and basement
membranes regulate various cellular processes, including
differentiation, proliferation and apoptosis.
In human, two nidogen proteins, nidogen-1 (150 kDa)
and nidogen-2 (200 kDa), have been identified. The two
proteins share a 46% primary sequence identity and a very
similar three dimensional structure, consisting of three
globular domains connected by a flexible link and a rod
[8,9].
Both nidogens are co-expressed in various tissues and
interact with collagens I and IV and perlecan at compara-
ble level. Differently, in vitro binding of nidogen-2 to lam-
inin γ1 is weaker than for nidogen-1. Also, nidogen-2,
differently from nidogen-1, does not interact with fibu-
lins. Both nidogens are also cell-adhesive. The above fea-
tures indicate that the two proteins might fulfill similar if
not identical functions, may be interchangeable in many,
but not all the cases and may compensate each other defi-
ciency [10,11]. This suggestion is confirmed by the find-
ings that both nidogen-1 and nidogen-2 are ubiquitous
components of basement membranes underneath epithe-
lia of most of the major organ systems [10]. Furthermore,
while deficient mice for either nidogen-1 or nidogen-2
[12,13] have no overt phenotypic abnormalities and base-
ment membranes appear to be normal, preliminary
reports of double mutants indicate a perinatal lethal phe-
notype and altered basement membrane ultrastructure
[12]. At least in the case of nidogen-1 knock-out, nidogen
2 compensation was demonstrated. An increase in
nidogen-2 expression and unexpected high affinity of
nidogen-2 for laminin γ1 was discovered, thus explaining
the lack of phenotype of the NID1-null mice [11].
In spite of the fact that it is established that abnormal stro-
mal microenvironment contributes to tumor formation
and progression and nidogens play a key role in the main-
tenance of the structural integrity of basement mem-
branes, which establish a barrier for cell movement,
migration and invasion, nidogen defects have not been
linked to human cancer. Here, we report that methylation
of nidogen 1 and 2 promoters is responsible for loss of
their gene expression and is frequent in human gastroin-
testinal tumors.
Materials and methods
Cell lines
The cell lines used in this study were MCF7, MDA-MB-231
and BT-20 from breast carcinoma, SW48 and RKO from
colon carcinoma, HEP3B from hepatocellular carcinoma,
RT4 from bladder carcinoma, SiHa and HeLa from cervi-
cal carcinoma, SK-LU-1 from lung carcinoma, HEY from
ovary carcinoma, G401 from a renal rhabdoid tumor,
U937 from a histiocytic lymphoma, K562 from a blast cri-
sis of a chronic myeloid leukemia, G361 from a
melanoma, RD from a rhabdomyosarcoma. These cell
lines were obtained from the American Type Culture Col-
lection (ATCC) and grown in Iscove Medium (Sigma-
Alldrich) supplemented with 10% Fetal Bovine Serum
(Sigma-Alldrich) at 37°C in 5% CO2 atmosphere.
Treatment with zebularine and trichostatin
Treatment of cells with Zebularine (synthesized at the
Department of Pharmaceutical Sciences, University of Fer-
rara) was carried out for 72 hours at 500 µM concentra-
tion. Trichostatin (TSA) (Sigma-Alldrich) treatment was
for 24 hours at 500 nM. When combined with zebularine,
TSA treatment was added during the last 24 hours. Imme-
diately after treatments, cells were harvested for DNA and
RNA purification.
Tumor and normal primary samples
Samples from primary tumors and non-neoplastic speci-
mens were from colorectal, gastric tissues, and from
peripheral blood leukocytes. Unselected gastric carcino-
mas were collected from 20 patients. Colorectal carcino-
mas (CRC) were collected from 49 patients. Additional
files 1 and 2 describe the characteristics of tumor samples.
Normal controls included biopsies of stomach mucosa
from 13 patients with gastric ulcers and colon mucosa
from 24 patients with diverticulosis. All patients included
in the study had a histological confirmed diagnosis.
Informed consent was obtained from each subject
included in the study.Molecular Cancer 2007, 6:17 http://www.molecular-cancer.com/content/6/1/17
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DNA purification and methylation specific PCR
Genomic DNA was isolated from cell lines and tissue by
standard treatment with sodium dodecyl sulfate and
EDTA in the presence of 200 µg/ml of proteinase K, fol-
lowed by phenol/chloroform extraction and ethanol pre-
cipitation. DNA from peripheral blood was isolated using
the Wizard genomic DNA purification kit (Promega) in
accordance with manufacturer's instructions. The methyl-
ation status of gene promoters was determined by Meth-
ylation Specific PCR (MSP) as described by Herman et al
[14]. The oligonucleotides for amplification of NID1 and
NID2 promoter regions are described in Table 1, their
location in the CpG island of the two genes is illustrated
in Figure 1 and detailed in Additional files 3 and 4. PCR
reactions were performed with the HotStar Taq polymer-
ase (Qiagen) in a total volume of 12 µl with the following
condition: 40 cycles of denaturation at 95°C for 30 sec,
annealing at temperatures indicated in Table 1 for 30 sec
and extension at 72°C for 1 min. For bisulfite sequencing
of NID1 promoter, after amplification with primers
NID1-UM-BFw2/NID1-UM-BRv1 (Table 1), PCR prod-
ucts were sequenced using primers NID1-UM-BFw2 or
NID1-UM-BRv1 using an automated sequencer ABI377.
RNA purification and RT-PCR
Total RNA was prepared using the TRIzol Reagent (Invit-
rogen Life Technologies, Carlsbad, CA) in accordance to
manufacturer's instructions. RNA was reverse transcribed
using Superscript II Reverse Transcriptase (Invitrogen,
Carlsbad, CA) in the presence of oligo-dT and random
primers. The primers used for NID1 and NID2 cDNA
amplification are shown in Table 1. Detection of the
GAPDH gene expression was used for cDNA quality con-
trol and normalization. Oligonucleotides for GAPDH
cDNA amplification were: GAPDH-RNA1107F (5'-CTA
TAA ATT GAG CCC GCA GCC-3') and GAPDH-
RNA1257R (5'-CCC AAT ACG ACC AAA TCC GT-3'). All
PCR reactions were performed with Hot Star Taq polymer-
ase (Qiagen) in a total volume of 12 µl, with the following
condition: 35 cycles (25 for GAPDH) of denaturation at
95°C for 30 sec, annealing at 60°C for 30 sec and exten-
sion at 72°C for 30 sec. Nucleotide sequence of PCR prod-
uct was determined to confirm specificity of RT-PCR
products.
Nidogen immunohistochemical analysis
Immunohistochemical analysis of nidogen-2 expression
was performed on formalin-fixed paraffin-embedded
tumor tissue sections using the ultraView Universal DAB
detection system and the BenchMark XT automated
immunostainer (Ventana Medical Systems, Tucson, AZ,
USA). Rabbitt antisera against nidogen-2 was produced by
one of the co-author (TS).
Results
Human cancer cell lines are methylated at the NID1 and 
NID2 promoters
We detected NID1 as a gene reactivated by treatment with
the demethylating agent zebularine in the human cancer
cell line MDA-MB-231 (data not shown). To confirm that
reactivation was induced by promoter demethylation, we
analyzed the methylation status of the NID1 promoter in
the MDA-MB-231 cell line and in several other human cell
lines. In addition, since two nidogen homologous genes
exist in the human genome, we also analyzed the methyl-
ation status of the promoter of the NID2 gene.
Both promoter regions of NID1 and NID2 genes include
a dense CpG island spanning about 2 kb around the first
exon (Figure 1). To determine whether aberrant methyla-
tion occurs at this region, we analyzed 16 human tumor
cell lines by methylation specific PCR (MSP) using the
primer sets MF/MR (Table 1 and Additional files 3 and 4).
56% (12/21) of the cell lines revealed methylation at the
NID1 promoter and 62% at the NID2 promoter (Figure
2A). Nucleotide sequence of PCR products confirmed the
methylation of all the cytosines within CpG dinucle-
otides. To determine whether methylation was associated
Table 1: NID1 and NID2 oligonucleotides for MSP and RT-PCR analyses
Gene Method Primer 1 Oligonucleotide sequencea Primer 2 Oligonucleotide sequence Product size T (°C) annealing
NID-1 MSP methyl NID1_MF GAGGGTTTCGTTTCGT
TTAGC
NID1_MR AACGCCGTTCGCTAAA
AATCG
144 58°C
NID-2 MSP methyl NID2_MF TAGTATTGGTAACGAC
GATAGTATC
NID2_MR AAATTCGAAACTAACG
CGACACG
141 58°C
NID-1 MSP unmethyl NID1_UF GAGGGTTTTGTTTTGTT
TAGT
NID1_UR AAAAACACCATTCACT
AAAAATCA
147 51°C
NID-2 MSP unmethyl NID2_UF TAGTATTGGTAATGATG
ATAGTATT
NID2_UR AAATTCAAAACTAACA
CAACACA
141 51°C
NID-1 RT-PCR NID1_181F AGGAGCTCTTTCCCTT
CGGC
NID1_354R CGGGGGTTCACTCGTA
GCAA
174 60°C
NID-2 RT-PCR NID2_722F TAGGCGCTTACGAGGA
GGTCAA
NID2_813R TATCAGACCCATCAGA
TGCCAAAAC
92 63°C
a All primers for MSP were designed on predicted bisulfite-modified DNA sequences (see Additional files 3 and 4)Molecular Cancer 2007, 6:17 http://www.molecular-cancer.com/content/6/1/17
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with loss of gene expression, we analyzed the expression
of the NID1 and NID2 genes by RT-PCR in the same 16
cell lines. We confirmed that the presence of promoter
methylation was associated with loss of gene expression
with only two exceptions: NID1 in the Hep3B cells and
NID2 in the HeLa cells. Furthermore, with the exception
of G401 and K562 for the NID2 gene, both genes were
expressed in the unmethylated cell lines, implicating a
direct relationship between promoter methylation and
loss of gene transcription. To confirm the role of DNA
methylation in gene transcriptional repression, we treated
MDA-MB-231 cells, where NID1 and NID2 are both
methylated, with the demethylating agent zebularine
alone or in combination with TSA. Indeed, demethylation
of the NID1 and NID2 promoters restored gene transcrip-
tion, demonstrating that promoter methylation was
responsible for the silencing of nidogen genes (Figure 2B).
NID1 and NID2 promoter methylation in human primary 
gastrointestinal neoplasms
We investigated the presence of aberrant methylation at
the NID1 and NID2 promoters in primary gastrointestinal
neoplasms. Data are summarized in Table 2 and repre-
sentative results are shown in Figure 3. By using MSP with
the MF/MR primer set (Table 1), we analyzed 49 colorec-
tal and 20 gastric carcinomas, as well as 13 gastric and 24
Schematic diagrams of the human NID1 and NID2 genes and their 5' CpG islands Figure 1
Schematic diagrams of the human NID1 and NID2 genes and their 5' CpG islands. Size of the genes and exon composition are 
shown in the upper parts of the schemes. In the lower parts, the 5' of the genes is enlarged and the presence of a dense region 
of CpG dinucleotides (a CpG island) is displayed. The CpG islands overlap with the first exons of the genes. Exons, arrowed 
boxes separated by thin lines; blue parts are non-coding regions, red parts are coding regions. CpG, each vertical bar repre-
sents the presence of a CpG dinucleotide. Arrows indicate the location of primers for MSP amplification (NID1 amplified 
region: from nt 986318 to nt 986461 of sequence NT_004836 version 17; NID2 amplified region: from nt 33535309 to nt 
33535449 of sequence NT_026437, versione 11). All primers were designed on predicted bisulfite-modified nucleotide 
sequence (see Supplemental Figures 1 and 2).Molecular Cancer 2007, 6:17 http://www.molecular-cancer.com/content/6/1/17
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(A) NID1 and NID2 promoter methylation and gene expression in human cancer cell lines Figure 2
(A) NID1 and NID2 promoter methylation and gene expression in human cancer cell lines. With few exceptions, there is a 
clear correlation between gene expression and lack of promoter methylation. Each sample was checked and confirmed for 
quality and equal cDNA amount used by analyzing expression of GAPDH by RT PCR amplification (GAPDH experiment was 
identical for both genes). (B) NID1 and NID2 genes are reactivated by the DNA demethylating agent zebularine. The panels 
show the effect of zebularine (ZEB) and trichostatin (TSA) on DNA demethylation and gene expression in the human cell line 
MDA-MB-231. Zebularine, alone or in combination with TSA, induced expression of both genes, which was absent in the 
parental untreated cell line and in the treatment with TSA alone. PBL, peripheral blood leukocytes, and the cell line A204 were 
used as positive controls. 123 bp, Molecular weight marker 123 bp ladder.Molecular Cancer 2007, 6:17 http://www.molecular-cancer.com/content/6/1/17
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colonic mucosas from non-neoplastic specimens. For the
NID1 gene, we detected promoter methylation in 67%
(33/49) of the colon and 90% (18/20) of the gastric carci-
noma samples. Methylation of this gene promoter was
also detected, at lower frequency and signal intensity, in
colon and gastric mucosas of non-neoplastic specimens.
Nucleotide sequencing of PCR products detected in nor-
mal tissues revealed only sporadic methylation at few
CpGs in the context of essentially non-methylated CpG
islands, while methylation was detected at all CpGs in
tumor samples (data not shown). For the NID2 gene, we
detected promoter methylation in 29% (14/48) of the
colon and 95% (19/20) of the gastric carcinoma samples.
No methylation of the NID2 gene promoter was detected
in colon and gastric mucosas from non-neoplastic speci-
mens.
To further confirm that aberrant nidogen methylation was
associated with cancer tissues, we analyzed DNAs derived
from dissected cancer, mucosa and muscolaris from the
same patient. These experiments confirmed that aberrant
methylation was confined to cancer tissue (Figure 4). Fur-
thermore, analysis of nidogen-2 by immunostaining in
primary tumors confirmed that only tumor samples pre-
senting aberrant methylation lacked nidogen expression
(Figure 5).
Discussion
Removal of basement membrane is essential for cell inva-
sion [15], a regulated process that occurs in trophoblast
implantation, organogenesis and angiogenesis [16]. In
tumorigenesis, invasion through the basement membrane
is a feature of malignancy [17]. Disruption of the integrity
of the basement membrane creates an invasion-permis-
sive environment, which may promote cancer cell prolif-
eration and invasion [18]. Basement membrane
abnormalities may cause an increase in tumor susceptibil-
ity [19] by bypassing the need for degradation of the base-
ment membrane and by triggering pro-proliferative effects
on tumor cells via interaction with stromal fibroblast
growth factors, cytokines, and/or matrix proteases [20].
Examples of abnormalities of basement membranes in
human cancer have been described. Malignant melano-
mas lacked basement membranes when they migrated
into the dermis, a process accompanied by a drastically
reduced staining for collagen type IV and nidogen [21].
Wilms' tumors are coated with a layer of amorphous
material that does not represent a basement membrane,
since it contains polysialic acid but not laminin, laminin-
nidogen complex, or low density proteoglycan [22]. The
role of basement membrane in normalization of tumor
cells was functionally proven, for example, by experi-
ments with pre-malignant breast epithelial cells, which
undergo growth arrest and differentiate in the presence of
a reconstituted physiological basement membrane [23].
Overall, these observations suggest that major alterations
in the composition of basement membranes are impor-
tant in tumor establishment or progression.
Here, we report for the first time that loss of nidogen
expression, a common basement membrane protein, is
frequent in human gastrointestinal tumors. The mecha-
nism underlying nidogen loss is aberrant promoter meth-
ylation of both NID1 and NID2 genes. Our results
indicate that aberrant methylation at nidogen genes is an
epigenetic defect that is absent in non-neoplastic mucosa
and muscolaris, and potentially imparts a selective advan-
tage to tumor cells. The lack of expression of nidogen pro-
teins, which are both present in the basement membranes
of the normal adult intestine [10], impairs the possibility
of compensation for constitution of basement membrane.
It has also been reported that nidogen can protect lam-
inin-1 against proteolysis [1], suggesting that nidogen
absence may cause additional basement membrane pro-
teins degradation and remodeling. Nidogen loss will cer-
tainly affect basement membrane structural integrity.
Potentially, this mechanism may facilitate the route to
invasion for genetically altered epithelial cells and favor
metastasis by promoting angiogenesis.
Table 2: NID1 and NID2 promoters DNA methylation
NID1 methylation (%) NID2 methylation (%)
Stomach, carcinoma 18/20 (90) 19/20 (95)
Stomach, normal mucosa 5/13 (38)* 0/13 (0)
Colon, carcinoma 33/48 (69) 14/48 (29)
Colon, normal mucosa 8/24 (33)* 0/24 (0)
* Generally, 10–100 fold weaker signals than in tumor samples. These samples displayed only few CpG dinucleotides methylated in an overall non-
methylated CpG islandMolecular Cancer 2007, 6:17 http://www.molecular-cancer.com/content/6/1/17
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Methylation at the NID1 and NID2 gene promoters in human colon and gastric cancer Figure 3
Methylation at the NID1 and NID2 gene promoters in human colon and gastric cancer. DNA methylation was detected by 
methylation-specific PCR. DNAs were modified by bisulfite treatment. PCR was performed using primers specifically designed 
to amplify the methylated forms (see Table 1). The frequency of aberrant methylation in normal and cancer samples is shown 
in Table 2. Molecular weight marker (123 bp), Controls were as indicated in Figure 2.
Methylation specific PCR for NID1 and NID2 promoter in  DNAs from tissue dissected cancer (Carc), mucosa (Muc)  and muscolaris (Musc) from the same patient, showing  strongly positive signals only in carcinoma samples and not in  mucosa and muscolaris (except a weak signal for NID1 in  mucosa) Figure 4
Methylation specific PCR for NID1 and NID2 promoter in 
DNAs from tissue dissected cancer (Carc), mucosa (Muc) 
and muscolaris (Musc) from the same patient, showing 
strongly positive signals only in carcinoma samples and not in 
mucosa and muscolaris (except a weak signal for NID1 in 
mucosa). Molecular weight marker (123 bp), Controls were 
as indicated in Figure 2.Molecular Cancer 2007, 6:17 http://www.molecular-cancer.com/content/6/1/17
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Immunohistochemistry analysis of nidogen-2 expression in human colon carcinomas Figure 5
Immunohistochemistry analysis of nidogen-2 expression in human colon carcinomas. (A) Sample 3405, a moderately differenti-
ated adenocarcinoma that does not present aberrant methylation of the NID2 gene promoter, shows a strong immunoreactiv-
ity for nidogen-2 in the stroma. (B) Sample 3413, a poorly differentiated adenocarcinoma that presents aberrant methylation of 
the NID2 gene promoter, shows a nearly complete lack of immunoreactivity for nidogen-2. (Original magnification, 200×).Molecular Cancer 2007, 6:17 http://www.molecular-cancer.com/content/6/1/17
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